Search Tag: AHRF

2024 16 Sep

  Noninvasive ventilation (NIV) is increasingly used to assist spontaneous breathing in patients with acute hypoxaemic respiratory failure (AHRF) and can reduce the need for intubation, mortality, and ICU stay. However, if NIV fails, it can increase mortality if intubation is necessary, and high respiratory effort not controlled by NIV might cause...Read more

2022 20 Sep

Acute hypoxaemic respiratory failure (AHRF) is one of the main manifestations of severe COVID-19. The RECOVERY trial showed that dexamethasone 6 mg/d for ten days reduced 28-day mortality in patients with the most severe COVID-19. Another study described the benefit of high-dose dexamethasone in ARDS. However, Munch et al. found no difference between...Read more

2022 19 Apr

High flow nasal oxygen (HFNO) has many physiological benefits in patients with acute hypoxaemic respiratory failure (AHRF). It can also help reduce the need for intubation. However, optimal flow settings are unknown and are generally based on expert recommendations.  Maintaining oxygenation within a given target range requires intensive patient...Read more

2021 07 Dec

Acute hypoxaemic respiratory failure (AHRF) is one of the most common causes of admission to the ICU. It has a mortality rate of nearly 30%. Non-invasive respiratory management strategies are recommended to avoid the risk of endotracheal intubation. However, patients with de novo acute hypoxaemic respiratory failure (AHRF) are often at high risk of...Read more